# Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

> **NCT02137850** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 124 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A

## Interventions

- **DRUG:** turoctocog alfa pegol

## Key facts

- **NCT ID:** NCT02137850
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-26
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-06-07
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137850, "Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02137850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*